Abstract
Ocular surface disease (OSD) is a common adverse event in dupilumab-treated patients with atopic dermatitis (AD). The pathomechanism remains unclear. At present, no data are available on dupilumab levels in the eyes of these patients. The aim of this study is to measure dupilumab levels in tear fluid after 4 and 28 weeks of dupilumab treatment. This prospective study included dupilumab-treated moderate-to-severe AD patients. Patients were seen by a dermatologist and an ophthalmologist at the start of dupilumab, and after 4 and 28 weeks of dupilumab treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
